InsiderSignalSign in
← Insider buys

Novo Holdings A/S has bought stock on 22 days since Jun 2016

10% owner at Avalyn Pharma Inc., and 30 other companies

SEC CIK 0001388325 · Filings on SEC.gov ↗

$174.7MBought
$339.2MSold
May 5Last buy

Novo Holdings A/S's record

3 months after each buy, from the first price a copier could get.

−23.1%Average
−23.1 ptsVs S&P 500
1 of 8Higher

8 buys since 2016 with 3 months of prices.

Companies

Every filing

65 filings since Mar 2016, newest first

AVLNBuy

Avalyn Pharma Inc.

10% owner

$10.0M+17.0%May 5
MPLTBuy

Maplight Therapeutics, Inc.

10% owner

$16.2M+35.0%Oct 30
IOBTSell

Io Biotech, Inc.

10% owner

$99K−2.0%Jul 26
SPRBSell

Spruce Biosciences, Inc.

10% owner

$351K−15.0%Mar 25
SPRBSell

Spruce Biosciences, Inc.

10% owner

$1.4M−37.0%Mar 20
SPRBSell

Spruce Biosciences, Inc.

10% owner

$1.7M−28.0%Mar 18
MGXBuy

Metagenomi, Inc.

10% owner

$13.0M+107.0%Feb 15
IOBTSell

Io Biotech, Inc.

10% owner

$988K−11.0%Feb 13
IOBTBuy

Io Biotech, Inc.

10% owner

$5.0M+76.0%Aug 11
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$280K−3.0%Jul 20
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$106K−1.0%Jul 18
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$529K−5.0%Jul 3
IRONSell

Disc Medicine, Inc.

10% owner

$57.6M−53.0%Jun 28
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$72K−1.0%Jun 28
RPHMSell

Reneo Pharmaceuticals, Inc.

10% owner

$710K−3.0%Jun 23
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$26KJun 23
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$34KJun 20
SPRBBuy

Spruce Biosciences, Inc.

10% owner

$7.0M+49.0%Feb 21
EWTXBuy

Edgewise Therapeutics, Inc.

10% owner

$5.0M+9.0%Sep 16
CYTSell

Cyteir Therapeutics, Inc.

10% owner

$2.7M−19.0%Jul 22
BOLTSell

Bolt Biotherapeutics, Inc.

10% owner

$1.6M−18.0%Jul 15
ACLXBuy

Arcellx, Inc.

10% owner

$12.5M+26.0%Feb 9
IOBTBuy

Io Biotech, Inc.

10% owner

$4.5M+11.0%Nov 10
UTRSBuy

Minerva Surgical Inc

10% owner

$7.0M+39.0%Oct 27
INGNSell

Inogen Inc

10% owner

$39.0M−25.0%Jun 3
SPRBSell

Spruce Biosciences, Inc.

10% owner

$6.6M−10.0%May 21
RPHMBuy

Reneo Pharmaceuticals, Inc.

10% owner

$10.0M+24.0%Apr 14
INGNSell

Inogen Inc

10% owner

$38.7M−22.0%Mar 3
GRTXSell

Galera Therapeutics, Inc.

10% owner

$5.3M−17.0%Feb 19
BOLTBuy

Bolt Biotherapeutics, Inc.

10% owner

$8.0M+10.0%Feb 11
INZYSell

Inozyme Pharma, Inc.

10% owner

$7.9M−15.0%Feb 1
GLTOBuy

Galecto, Inc.

10% owner

$5.0M+15.0%Nov 4
GRTXSell

Galera Therapeutics, Inc.

10% owner

$5.0M−13.0%Oct 19
HRMYBuy

Harmony Biosciences Holdings, Inc.

10% owner

$3.2M+3.0%Aug 25
CMPIBuy

Checkmate Pharmaceuticals, Inc.

10% owner

$7.5M+30.0%Aug 13
CRVSSell

Corvus Pharmaceuticals, Inc.

10% owner

$8.2M−53.0%Jul 9
MISTSell

Milestone Pharmaceuticals Inc.

10% owner

$3.8M−9.0%Nov 27
GRTXBuy

Galera Therapeutics, Inc.

10% owner

$6.0M+17.0%Nov 14
CRVSSell

Corvus Pharmaceuticals, Inc.

10% owner

$6.1M−34.0%Jul 25
MORFBuy

Morphic Holding, Inc.

10% owner

$10.0M+34.0%Jul 1
MISTBuy

Milestone Pharmaceuticals Inc.

10% owner

$5.0M+14.0%May 14
ETTXBuy

Entasis Therapeutics Holdings Inc.

10% owner

$16.3M+100.0%Oct 1
CRVSBuy

Corvus Pharmaceuticals, Inc.

10% owner

$10.0M+36.0%Mar 13
KALVSell

Kalvista Pharmaceuticals, Inc.

10% owner

$26.3M−100.0%Oct 12
KALVSell

Kalvista Pharmaceuticals, Inc.

10% owner

$1.3M−6.0%Sep 18
HTGMSell

Htg Molecular Diagnostics, Inc

10% owner

$2.1M−100.0%Aug 25
HTGMSell

Htg Molecular Diagnostics, Inc

10% owner

$167K−6.0%Aug 22
ANABSell

Anaptysbio Inc

10% owner

$7.5M−16.0%Aug 21
ANABSell

Anaptysbio Inc

10% owner

$3.8M−7.0%Aug 16
ANABSell

Anaptysbio Inc

10% owner

$10.4M−17.0%Aug 8
Older filings
About Novo Holdings A/S

Novo A/S, also referred to as Novo Holdings A/S, is a Danish investment firm and a major beneficial owner (BO) in various biotechnology companies, including a recent 10% stake in Maplight Therapeutics, Inc. (MPLT) as reported in Form 4 insider trading filings.( As a corporate insider, it has engaged in trading activities related to MPLT, reflecting its strategy of investing in life sciences and healthcare sectors.(

Novo Holdings A/S originates from the Novo Nordisk Foundation and manages significant assets, focusing on biotechnology, pharmaceuticals, and innovation to support long-term value creation in healthcare.( Its operations involve equity investments, venture capital, and ownership stakes in companies advancing treatments for chronic diseases like diabetes and obesity, leveraging deep roots in Denmark's pharmaceutical heritage through its association with Novo Nordisk A/S.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.